Varicella Zoster HHV-3 Infections Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)
Varicella Zoster (HHV-3) Infections Market is segemented By Drug Type (Marketed Drugs, Emerging Drugs), By Route of Administration (Intramuscular, Sub....
Varicella Zoster HHV-3 Infections Market Size
Market Size in USD
CAGR4.3%
| Study Period | 2024 - 2031 |
| Base Year of Estimation | 2023 |
| CAGR | 4.3% |
| Market Concentration | Medium |
| Major Players | Cangene Corporation, Novartis, GC Biopharma Corp, Pascoe Pharmazeutische Praeparate GmbH, SK Chemical Co. Ltd |
please let us know !
Varicella Zoster HHV-3 Infections Market Analysis
The Global Varicella Zoster (HHV-3) Infections Market is estimated to be valued at USD 1.79 billion in 2024 and is expected to reach USD 2.52 billion by 2031, growing at a compound annual growth rate (CAGR) of 4.3% from 2024 to 2031. The market is expected to expand due to the increasing number of people suffering from Varicella Zoster virus infections globally. With a rise in the elderly population who are at high risk of shingles, and the availability of effective vaccines for chickenpox and herpes zoster, the market is likely to witness lucrative growth opportunities over the forecast period.
The global Varicella Zoster infections market is expected to experience positive growth trends over the next few years. There is an increasing awareness among people about the viral infection and availability of treatment options. Moreover, continuous investments by leading manufacturers for development of novel and improved vaccines and drugs for effective management of VZV infections will further drive the market growth.